Track Prenetics Global Limited Class A Ordinary Share — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Prenetics Global Limited Class A Ordinary Share PRE · Stock Open Prenetics Global Limited Class A Ordinary Share in new tab

16.93 USD
Add to portfolio
EPS
-3.63
P/B
2.77
ROE
-40.77
Beta
0.24
Key Metrics
Earnings dateSept. 11, 2026
EPS-3.63
Book Value7.13
Price to Book2.77
Debt/Equity0.38
% Insiders13.825%
Growth
Revenue Growth1.08%
Estimates
Forward P/E-29.04
Forward EPS-0.68

DCF Valuation

Tweak assumptions to recompute fair value for Prenetics Global Limited Class A Ordinary Share (PRE)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Prenetics Global Limited Class A Ordinary Share Analysis (PRE)

Hong Kong Health Care Stock

Is Prenetics Global Limited Class A Ordinary Share a good investment? Prenetics Global Limited Class A Ordinary Share (PRE) is currently trading at 16.93 USD.

Earnings Schedule: Prenetics Global Limited Class A Ordinary Share is expected to release its next earnings report on Sept. 11, 2026. The market consensus estimate for Forward EPS is -0.68.

Investor FAQ

Does Prenetics Global Limited Class A Ordinary Share pay a dividend?

No, it does not currently pay a dividend.

What asset class is Prenetics Global Limited Class A Ordinary Share?

Prenetics Global Limited Class A Ordinary Share is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Sept. 11, 2026. The company currently has a trailing EPS of -3.63.

Company Profile

Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Trades
No dividend information available for this instrument.

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion